Loss of the sphingolipid desaturase DEGS1 causes hypomyelinating leukodystrophy

Devesh C. Pant, … , Odile Boespflug-Tanguy, Aurora Pujol

*J Clin Invest.* 2019. [https://doi.org/10.1172/JCI123959](https://doi.org/10.1172/JCI123959).

Graphical abstract

Find the latest version:

http://jci.me/123959/pdf
Loss of the sphingolipid desaturase DEGS1 causes hypomyelinating leukodystrophy

Devesh C Pant PhD1,2, Imen Dorboz PhD3, Agatha Schluter PhD1,2, Stéphane Fourcade PhD1,2, Nathalie Launay PhD1,2, Javier Joya PhD1,2, Sergio Aguilera-Albesa MD4, Maria Eugenia Yoldi MD4 Carlos Casasnovas MD1,2, Mary J. Willis MD5,Montserrat Ruiz PhD1,2, Dorothée Ville MD6, Gaetan Lesieur-Pernet PhD8,9, Isabelle Desguerre MD8,9, Huifang Yan PhD10,11, Jinming Wang PhD10,11, Margit Burmeister PhD10,11, Laurent Brady PhD12, Mark Tarnopolsky MD13, Carles Cornet MSc14, Davide Rubbini PhD14, Javier Terriente PhD14, Kiely N. James MSc15, Damir Musaev PhD15, Maha S. Zaki MD16, Marc C Patterson MD17, Brendan C Lanpher MD18, Eric W Klee PhD18,19, Filippo Pinto e Vairo MD18,19, Elizabeth Wohler MS20, Nara Lygia de M. Sobreira MD21, Julie S. Cohen MSc22, Reza Maroofian PhD23, Hamid Galedhari PhD24, Neda Mazaheri MSc24,25, Gholamreza Shariati MD25,26, Laurence Colleaux PhD8,9, Diana Rodriguez MD27,28, Joseph G. Gleeson MD15, Cristina Pujades PhD29, Ali Fatemi MD22,30, Odile Boespflug-Tanguy MD31 and Aurora Pujol MD1,2,32*

1Neurometabolic Diseases Laboratory, Bellvitge Biomedical Research Institute (IDIBELL), 08908 L'Hospitalet de Llobregat, Barcelona, Catalonia, Spain
2Center for Biomedical Research on Rare Diseases (CIBERER), ISCIII, Madrid, Spain
3INSERM UMR 1141, DHU PROTECT, Paris Diderot University, Sorbonne Paris Cité, Paris 06, Paris, France.
4Pediatric Neurology Unit, Department of Pediatrics, Navarra Health Service, Navarrabiomed, Pamplona, Spain.
5Department of Pediatrics, Naval Medical Center San Diego, San Diego, CA, USA.
6Department of Neuropediatrics, Lyon University Hospital, Lyon, France
7Department of Medical Genetics, Lyon University Hospital and GENDEV team CNRS UMR 5292, INSERM U1028, CRNL, and University Claude Bernard Lyon 1, Lyon, France
8Paris Descartes - Sorbonne Paris Cité University, Imagine Institute, Paris, France
9Laboratory of developmental brain disorders, INSERM UMR 1163, Paris, France
10Department of Psychiatry, University of Michigan, Ann Arbor, MI, USA.
11Department of Human Genetics, University of Michigan, Ann Arbor, MI, USA
12Department of Pediatrics (Neuromuscular and Neurometabolics), McMaster Children's Hospital, Hamilton, Ontario, Canada.
13Departments of Pediatrics (Neuromuscular and Neurometabolics), and Medicine, McMaster University, Hamilton, Ontario, Canada.
14ZeClinics SL, PRBB, Barcelona, Spain
15Laboratory for Pediatric Brain Disease, Department of Neurosciences, Howard Hughes Medical Institute, University of California, San Diego, CA, USA.
16Human Genetics and Genome Research Division, Clinical Genetics Department, National Research Centre, Cairo, Egypt.
17Departments of Neurology and Pediatrics, Mayo Clinic, Rochester, MN, USA.
18Department of Clinical Genomics, Mayo Clinic, Rochester, MN, USA.
19Center for Individualized Medicine, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
20McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
McKusick-Nathans Institute of Genetic Medicine, and Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Moser Center for Leukodystrophies at Kennedy Krieger Institute, 707 North Broadway, Baltimore, MD, 21205, USA.

Genetics Research Centre, Molecular and Clinical Sciences Institute, St George’s, University of London, London, UK

Department of Genetics, Faculty of Science, Shahid Chamran University of Ahvaz, Ahvaz, Iran

Narges Medical Genetics and Prenatal Diagnosis Laboratory, East Mihan Ave., Kianpars, Ahvaz, Iran

Department of Medical Genetics, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

APHP, Department of Neuropediatrics, National Reference Center for Neurogenetic Disorders, Hôpital Armand-Trousseau, GHUEP, Paris, France.

GRC ConCer-LD, Sorbonne Universités, UPMC Université, Paris, France

Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain

Department of Neurology, Johns Hopkins Medical Institutions, Baltimore, MD, USA

Assistance Publique des Hopitaux de Paris (APHP), Reference Center for "Leukodystrophies and rare leukoencephalopathies," (LEUKOFRANCE), Hôpital Robert Debré, Paris, France.

Catalan Institution of Research and Advanced Studies (ICREA), Barcelona, Catalonia, Spain

*Correspondence should be addressed to:
*Professor Aurora Pujol, Neurometabolic Diseases Laboratory, IDIBELL, Hospital Duran i Reynals, Gran Via 199, 08908 L’Hospitalet de Llobregat, Barcelona, Spain.
Tel: +34 932607137; Fax: +34 932607414; Email: apujol@idibell.cat

*Professor Odile Boespflug-Tanguy, INSERM UMR 1141, DHU PROTECT, Paris Diderot University, Sorbonne Paris Cité, France
Email: odile.boespflug-tanguy@aphp.fr
ABSTRACT
Sphingolipid imbalance is the culprit in a variety of neurological diseases, some affecting the myelin sheath. We have used whole exome sequencing in patients with undetermined leukoencephalopathies to uncover the endoplasmic reticulum lipid desaturase \textit{DEGS1} as the causative gene in nineteen patients from thirteen unrelated families. Shared features among the cases include severe motor arrest, early nystagmus, dystonia, spasticity and profound failure to thrive. MRI showed hypomyelination, thinning of corpus callosum and progressive thalami and cerebellar atrophy, suggesting a critical role of \textit{DEGS1} in myelin development and maintenance. This enzyme converts dihydroceramide (DhCer) into ceramide (Cer) in the final step of the \textit{de novo} biosynthesis pathway. We detected a marked increase of the substrate DhCer and DhCer/Cer ratios in patient’s fibroblasts and muscle. Further, we used a knockdown approach for disease modelling in \textit{Danio rerio}, followed by a preclinical test with the first-line treatment for multiple sclerosis, fingolimod (FTY720, Gilenya®). The enzymatic inhibition of ceramide synthase, one step prior to \textit{DEGS1} in the pathway, by fingolimod, reduced the critical DhCer/Cer imbalance and the severe locomotor disability, increasing the number of myelinating oligodendrocytes in the zebrafish model. These proof-of-concept results pave the way to clinical translation.

Keywords
\textit{DEGS1}; Hypomyelinating Leukodystrophy; Sphingolipids; Ceramides; Fingolimod
Introduction

Leukodystrophies (LD) are a heterogeneous group of rare, heritable disorders of all ages that primarily affect the brain’s white matter, often leading to motor and cognitive impairment in early childhood and progression to severe disability over time (1, 2). All modes of inheritance, broad pathogenic mechanisms, and complex cellular interactions underlie LD, yet many cases remain unexplained with an unknown biochemical or molecular basis (3). With progress in clinical genomics, new forms of ultra-rare leukodystrophies are being recognized (4-6), and advances in novel technologies in gene, cell and enzyme therapy hold promise for improving patient management (7, 8).

Using whole exome sequencing (WES), we have identified homozygous or compound heterozygous pathogenic variants in the DEGS1 gene in nineteen leukodystrophy patients from thirteen unrelated families. DEGS1 was first cloned in 1996 from Drosophila melanogaster, and was given the name “drosophila degenerative spermatocyte 1” or DEGS1 (9). It encodes a Δ4-dihydroceramide desaturase (OMIM 615843) mapping to chromosome 1q42.11, also known as DES1. This enzyme catalyzes the insertion of a Δ 4,5-trans double bond into dihydroceramide (DhCer) to convert it to ceramide (Cer), in the final step of the de novo ceramide biosynthesis pathway (Figure 1) (10).

Biosynthesis of Cer, made of a sphingoid base and a fatty acid, mainly occurs via three distinct pathways: a) the de novo pathway, which takes place in the endoplasmic reticulum (ER) and uses palmitoyl-CoA and serine as its precursors; b) the sphingomyelinase pathway, which takes place in the plasma membrane, Golgi apparatus and mitochondria, and converts sphingomyelin into Cer bi-directionally; and c) the salvage pathway, which converts complex sphingolipids species into Cer and recycles the acyl moiety of ceramides in both lysosomes and endosomes (Figure 1) (11). This compartmentalization of the more than 200 structurally distinct ceramides suggests a high complexity of regulation and function, which is only beginning to emerge (12, 13).

Cer is the central unit of all sphingolipids, serving as a building block and as a hub for bioactive, more complex lipidic species. The biosynthesis of Cer is followed by the addition of sugar moieties to generate glucosylceramide and galactosylceramide, which undergo further transformation into gangliosides and sulfatides, respectively. Galactosylceramides and sulfatides with very long N-acyl chains, in particular C24:0 and C24:1, are the most abundant myelin lipid components (14, 15). Indeed, defects of
galactosylceramidase and arylsulfatase A, one and two steps after DEGS1 respectively, cause Krabbe disease/globoid leukodystrophy (GLD) and metachromatic leukodystrophy (MLD) (Figure 1), two well-characterized demyelinating LD. Beyond the myelin sheath, sphingolipids are involved in numerous biological processes related to cell survival, metabolic regulation and adaptation to stressors (16). The importance of sphingolipids in neurodegenerative disease has recently expanded beyond lysosomal disorders or classical sphingolipidosis. Secondary disturbances of these lipid species including DhCer have been shown in Huntington disease (17) and Alzheimer’s patients (18).

Evidence from studies in animal models supports an essential role of DEGS1 in development (19, 20). Homozygous Degs1−/− mice die within the first 8 weeks of age, presenting a complex phenotype, including small size, scaly skin, sparse hair and tremors (19). Lipidomics analysis showed that Degs1−/− mice exhibit accumulation of DhCer and higher DhCer/Cer ratio in several tissues (19), similarly to the Drosophila melanogaster model (20).

Our patients presented with hypomyelinating LD with progressive atrophy of corpus callosum (CC), thalami and cerebellum, severe failure to thrive and peripheral neuropathy. Using patients’ fibroblasts, we functionally validated variants by testing their impact on DhCer/Cer ratios and reactive oxygen species (ROS) production. Importantly, treatment with fingolimod (FTY720), a drug targeting sphingolipid metabolism and broadly used treatment for relapsing-remitting multiple sclerosis (MS), improved the metabolic imbalance, numbers of myelin-producing oligodendrocytes and locomotor deficits in the zebrafish model.
Results

Bi-allelic deleterious variants of DEGS1 in patients with brain white matter abnormalities

As part of our ongoing studies on the molecular basis underlying undiagnosed leukoencephalopathies, we identified a total of 19 individuals from 13 unrelated families with rare variants suspected to alter DEGS1 function (Figure 2; Table 1-2). The first patient under investigation was a female who presented feeding difficulties since birth, extreme irritability, hypertonia with opisthotonus, and nystagmus, resulting in death at 18 months. Severe hypomyelination was observed in the central and peripheral nervous system in the MRI and nerve conduction studies (Individual 6, Table 1-3). Extensive diagnostic investigations were negative. We thus carried out WES (see Experimental Procedures) in the proband, with subsequent Sanger validation and segregation analysis (Supplementary Figure 1). We identified an homozygous frameshift variant in DEGS1 (GenBank ID: NM_003676.3, c.604delT; p.(Tyr202Thrfs*8)) that was not present in the genome aggregation database (GnomAD; >246,000 chromosomes), the NHLBI Exome Variant Server (EVS; >13,000 alleles), or the Exome Aggregation Consortium (ExAC) database (ExAC> 60.706 individuals). No homozygous loss-of-function (LoF) variants were present for this gene in the mentioned databases. Personal communication with international Reference Centers for Leukodystrophies and information exchange on the GeneMatcher (21) platform facilitated the identification of 18 additional affected individuals with DEGS1 variants from various ethnic backgrounds who displayed overlapping phenotypes. These variants were present in a homozygous or compound heterozygous manner in thirteen families and segregated in the recessive inheritance mode. Consanguinity was present in 2/3 of the families. All consanguineous families harbor a homozygous variant except family 9.

DEGS1 encodes an evolutionary conserved sphingolipid desaturase of 323 AA containing six transmembrane domains, three histidine motifs, a lipid desaturase domain and a fatty acid desaturase (FAD) domain (Figure 2). The highly-conserved histidine motifs HX(3-4)H, HX(2-3)HH, and H/QX(2-3)HH, are essential for catalytic activity (10). Twelve out of thirteen variants are located in the FAD domain, and only one, p.(Met37Thr), is located in the sphingolipid delta4-desaturase domain. The most prevalent DEGS1 variants in our cohort were p.(Asn255Ser) and p.(Trp107*), identified
in three and two independent families, respectively. Eight out of thirteen variants have not been identified in control populations, and the rest of the variants have a MAF lower than 0.0001, with none being found in the homozygous state in the ExAC, GnomAD, 1000 Genomes, Iranome or GME Variome databases. Seven out of thirteen variants are nonsense with four stopgain and three frameshifts. Six out of thirteen variants are missenses with high deleteriousness predicted by most of the 15 in silico tools tested (Supplementary Table S1).

Clinical features

Among the 19 affected patients, age of onset was at 5.6 months (+/- 7.2 m; 0.5-24 months) with variable disease severity. Fifteen of the patients (79 %) presented a severe form characterized by a very poor psychomotor development, dystonia and severe spasticity (Table 1-2 and Supplementary Video). All except one subject presented early nystagmus or abnormal eye movements between 1 and 6 months of age. Seizures were frequently observed (80%) around 2 years of age with a pharmacoresistant epilepsy sensitive to ketogenic diet in only 3 cases. In this group, failure to thrive was the most worrying clinical issue after 2 years of age despite feeding through gastrostomia. Head circumference was relatively conserved with acquired microcephaly (< 2 DS) in only 3 cases. Death occurred in 4 patients (26%) at a mean age of 4.6 years (+/-1.9; 2.5-7 y). These 4 patients harbored LoF variants (Table 1-2).

In the remaining 22% of the patients (patients 3, 7, 8, 14), a less severe phenotype was observed. Acquisition was better with capacity to sit or walking and to use a verbal communication. Progressive spasticity developed rapidly in these patients leading to motor degradation at various ages (2 to 16y). None presented with growth impairment (<2SD) or microcephaly (Table 1-2).

Cerebral MRI images were available for review by expert clinicians (AF, SAA, CC, DR, OBT) for 18 patients at mean age 3.6 y (+/-4.2; 0.5-17 y) (Table 3). All patients showed T2/FLAIR hyperintense white matter lesions with a normal hyperintense T1 indicative of an hypomyelinating form of LD (Figure 3 and Supplementary Figure 2) (22). In the 3 mildest clinical forms of the disease (patients 7, 8, 14), the abnormal WM signal affected the deep white matter with a relative preservation of the subcortical regions (Figure 3A, patient 7). In two severe cases a demyelinating aspect of the posterior subcortical-deep WM was noticed on T1 (Supplementary Figure 2, patients 4 and 10). Despite the severity of the clinical
symptoms, myelination progressed in the 6 patients analyzed with 2 or more MRI and a mean follow up of 4.2 y (+/-3.5 y; 1-10 y) (Figure 3B and Supplementary Figure 2).

Basal ganglia abnormalities were observed in only the most severe forms. Abnormal hyper T2/FLAIR signal and atrophy of the thalami were the most frequent findings (11/15 cases, 73%) (Figure 3, Table 3, Supplementary Figure 2). Two severe patients (patient 2 and 19) showed an associated hypoT2/FLAIR in the pallidi (Table 3).

Thinning of the CC was observed in 76% of cases associated with progressive vermicran cerebellar atrophy in 41% of cases (Figure 3, Supplementary Figure 2). Demyelinating neuropathy with nerve conduction below 35m/s was observed in 5 out of the 14 patients analyzed by EMG/NCV (1/3). The evoked potentials performed in 7 patients (4 BAEP; 5 VEP; 1 SEP) demonstrated long latencies in the central conduction (> 3 SD) in all cases (Table 1-2).

**Genotype-phenotype correlation**

Patients from the same families (Table 1-2, see families 1, 3, 5, 8, 10) as well as patients with the same genotype (Table 1-2, see Algerian families 6 and 7; Egyptian families 8 and 12), expressed the same phenotype. Patients 2, 6, 11 and 12 who harbored homozygous LoF variants in the FAD domain, died at 7 years, 18 months, 2.5 and 5 years of age respectively, indicating a likely phenotype-genotype correlation. At the other end of the spectrum we found patient 3, a 9-year-old girl with p.(Arg133Trp) and p.(Leu251Phefs*10) variants in trans, who presented with developmental regression from 9 months of age; however she was able to sit without help and communicate using simple sentences. Her MRI and spectroscopy were almost normal at 4 and 5 years of age and presented no signs of peripheral neuropathy.

**DEGS1 activity is impaired in patients’ fibroblasts and muscle**

To verify the impact of the variants on DEGS1 protein function, we used targeted lipidomics to quantify dihydroceramides and ceramides, the substrates and products of DEGS1 respectively. The results indicate a slight reduction of ceramides (Cer) concomitant with an important accumulation (3 to 9 fold) of dihydroceramides (DhCer) in cultured skin fibroblasts of affected individuals (patients 4, 7, 9) and muscle tissue (patient 3). Thus, the activity of the DEGS1 enzyme, represented as the DhCer/Cer ratio, was greatly decreased in all cases (Figure 4A-B), consistent with the notion that the variants identified caused reduced activity of the DEGS1 enzyme.
Impaired function of DEGS1 induces intracellular ROS production

Excess of dihydroceramides has been recently reported to generate ROS in *Drosophila ifc* KO photoreceptors (20). We observed that ROS production was increased in all patients’ fibroblasts (patients 4, 7 and 9) compared to controls (Figure 4C), using the probe H$_2$DCFDA which measures singlet oxygen, superoxide, hydroxyl radical and various peroxides and hydroperoxides (23). To gain insight into the direct consequences of DhCer accumulation in our system, we incubated control and patients fibroblasts with a long-chain DhCer (C18:0-DhCer) for 6h, at a dose of 20 µM. This dose increased ROS production in control fibroblasts although we could not discern an increase in the patient fibroblasts (Figure 4D). At higher doses, we found toxic effects in the fibroblasts independent of phenotype. This result confirmed that DhCer excess can generate ROS in human fibroblasts, whereas the blunted response in patient fibroblasts may follow saturation effects due to the steady-state accumulation of DhCer.

**Degs1 is highly expressed in the central nervous system (CNS)**

We performed RT-qPCR expression studies in different child and adult control human CNS tissues (n=2), to find specific expression of this gene in frontal lobe BA9, putamen, entorhinal cortex, hippocampus, hypothalamus, pons, cerebellum, white matter frontal cortex, spinal cord (Supplementary Figure 3A). This is consistent with the expression of *Degs1* mRNA in different tissues of 4 month old wild type mice (n=3), with high expression in the CNS, in particular in spinal cord, brain cortex, pons, cerebellum and hippocampus, compared to other organs (Supplementary Figure 3B). We next performed RT-qPCR to assess the *DEGS1* mRNA expression in fibroblasts from affected individuals (patients 4, 7 and 9) and healthy age-matched control individuals. We observed a 50% decrease in patient 4 (Supplementary Figure 3C), possibly owing to mRNA decay in the allele bearing the stop variant. We also analyzed the expression of *DEGS2*, the closest paralog of *DEGS1*, which is reported to have a partially overlapping, low C4-desaturase activity while showing a high C4-hydroxylase activities (24, 25). We corroborated a high expression of DEGS2 in small intestine and kidney (24), comparable to *DEGS1* (Supplementary Figure 3B), and two orders of magnitude lower expression in mouse brain and human fibroblasts as compared to *DEGS1*, which argues against any putative, physiologically relevant compensatory role of *DEGS2* (Supplementary Figure 3B-C).
Loss of *Degs1* in zebrafish causes DhCer/Cer imbalance, reduced number of oligodendrocytes and locomotor impairment

We investigated the suitability of a zebrafish model for this disease, since many of the genetic pathways for myelin development and maintenance are conserved (26). There is a single zebrafish ortholog of human DEGS1 (NP_997865.1), sharing a 74% protein identity with human DEGS1 (NP_003667.1). *In situ* hybridization (ISH) studies showed that *Degs1* was expressed in the dorsal part of the zebrafish brain, being more prominent in the dorsal thalamus, the posterior tuberculum, the tectum opticum, the hindbrain and the spinal cord (Supplementary Figure 4A-B). Using a transgenic strain expressing EGFP under the control of the myelin basic protein (mbp) promoter labeling myelinating oligodendrocytes (MBP⁺) (27), we found overlapping pattern of *Degs1* to MBP⁺ cells (Supplementary Figure 4C-F). Thus, we knocked down *Degs1* in zebrafish, by designing an efficient splice-blocking morpholino (MO) (Supplementary Figure 4G-I). Downregulation of DEGS1 induced an increase of DhCer and of the DhCer/Cer ratio (Figure 5A) at 5 days post-fertilization (5 dpf). Moreover, a high percentage of MO-DEGS1 larvae displayed an abnormal morphology (Figure 5B-C).

Next, phenotype and swimming ability of MO-DEGS1 zebrafish larvae was analyzed by measuring the total movement distance and by comparing the activity displayed by uninjected, and MO-control injected larvae. The total movement distance (mm) in MO-DEGS1 larvae was very significantly reduced (Figure 5D-E). Importantly, when embryos were injected with 10 ng of MO-DEGS1, no significant differences were observed in the survival rate compared to embryos injected with MO-controls or uninjected animals. To test the effect on myelination of the knockdown of DEGS1 in zebrafish, we measured the number of MBP⁺ cells in the spinal cord at 4.5 dpf after MO-DEGS1 injection (27). Interestingly, we found that the number of MBP⁺ cells was reduced by 30% in MO-DEGS1 compared to control larvae (Figure 5F-G’). Altogether, these results indicate that loss of DEGS1 function in zebrafish larvae results in some ten-fold increased DhCer/Cer ratio, locomotor disability and impaired myelination, consistent with the patients’ phenotype.

**FTY720 ameliorates in the phenotype of MO-DEGS1 zebrafish, while reducing ROS levels in patient fibroblasts**
Drug screening in zebrafish has been successfully used to identify target pathways as well as therapeutic compounds for human diseases (28). In an attempt to provide a therapeutic option for this life-threatening condition, we chose an FDA-approved drug targeting the de novo ceramide biosynthesis pathway, fingolimod (FTY720). This pleiotropic drug is reported to act as an inhibitor of the enzyme prior to DEGS1, the ceramide synthase (CerS) (Figure 1) (29). We used concentrations of 3·3, 1·0 and 0·3 ng/µl of FTY720, from birth to 120 hpf, without observing deleterious effects on survival. Also the number of MBP⁺ signals along the spinal cord was raised in MO-DEGS1 larvae after treatment, approaching the number of MBP⁺ cells in control larvae (Figure 5F-J). The locomotor deficit of MO-DEGS1 larvae was remarkably ameliorated after 5 days of treatment with FTY720 at 1·0 ng/µl (Figure 6A-B). This recovery correlated with an amelioration of total DhCer levels and ratios of DhCer/Cer upon treatment (Figure 6C). The effect of the drug was more marked towards some DhCer species (the saturated and monounsaturated C16-, C17-, C18-, C20-, C22-, C24-, C26-, C28-DhCer), which also accumulated the most. Of note, a ten fold decrease of C10-Cer was also observed, and recovered with treatment (Supplemental Table S2). Next, we tested a potential protective effect of FTY720 on ROS generation in DEGS1-fibroblasts (patients 4, 7 and 9 as above), by using a dose of 5 µM for 6 h and measuring the ROS levels as described above. FTY720 treatment prevented the elevation of ROS levels in patient fibroblasts (Figure 6D), while no effect was seen in control fibroblasts. These results provide proof of principle that FTY720 reduces the accumulation of DhCer and, thus, results in diminished ROS production at the cellular level.
Discussion

This study highlights the interest of using freely accessible information exchange platforms such as GeneMatcher after exome sequencing, for rapid identification of molecular causes of ultrarare disorders and collection of sufficient cases to delineate a disease spectrum and improve management (30).

Patients with DEGS1-related LD shared clinical and MRI features of hypomyelinating LD. In this heterogeneous group of LD, a large clinical spectrum of disease severity has been described in terms of defective myelination and axonal suffering. A large majority of our DEGS1 patients present the severe form of hypomyelinating LD, accompanied by thin CC and cerebellar atrophy as observed with TUBB4-related LD (31). However, the hypomyelination observed in TUBB4, as well as in the severe forms of PLP1-related LD, is more diffuse and remains stable over time (32). The relative preservation of the subcortical white matter relative to the clinical severity of DEGS1-patients may represent an interesting MRI diagnostic feature. Likewise, the observed improvement in myelination in our patients contrasts with the progressive atrophy affecting first the CC, then thalami and cerebellum, and finally the whole brain. This suggests a critical role of DEGS1 and ceramide metabolism in myelin development and maintenance, but also in neuronal/axonal functioning. The hypomyelinating pattern of the deep WM and the T2 hyperintensities of the thalamic regions are also observed in infantile GM1/GM2 gangliosidosis (22, 33). Finally, the association of central and peripheral demyelination are the hallmarks of disorders of sphingolipid metabolism (MLD and GLD), and of the peroxisomes (34). Although individual features in the DEGS1-related patients are not specific, their combination results in a defined pattern distinguishable from other LD.

The importance of maintaining sphingolipid balance for the nervous system is well exemplified in the lysosomal disorders such as Gaucher, Niemann Pick or Farber, all one enzymatic step away from DEGS1 (Figure 1) (8). Indeed, in many lipid storage disorders, deficiency or malfunctioning of one of the enzymes involved in sphingolipid metabolism results in accumulation of the corresponding lipid substrate leading to cellular dysfunction and death. Accumulation of DhCer is involved in many stress signals such as cell cycle regulation, autophagy induction, apoptosis and ROS generation (35, 36); the latter being substantiated by our results. Redox imbalance is intertwined with energy homeostasis in diseases of myelin (23, 37), and may play a role in the cachexia observed, in the large majority of our patients. Moreover, suppressing
DEGS1 led to cell cycle arrest, cell growth inhibition and apoptosis in cell culture models (16, 38), which may explain the decrease of myelinating MBP+ oligodendrocyte numbers and perhaps contribute to the general developmental delay and impressive failure to thrive in our patients. Concerning the biogenesis and stability of the myelin sheath, an enhanced proportion of DhCer (in particular C16-DhCer) has recently been shown to destabilize model membranes by increasing permeability and the formation of rigid domains (35). Of note, C16-DhCer is increased in our MO-DEGS1 model and lowered by fingolimod treatment (Supplementary Table S2). It is therefore tempting to posit that the exquisitely regulated process of myelin sheath biogenesis and compaction, including the lipid-lipid and lipid-protein interactions with major protein players such as MBP, MAG or PLP (14, 39), is likely to be severely disturbed, simply by the biophysical consequences of the DhCer/Cer imbalance on the cellular membranes.

Further, it has been recently shown that in the Drosophila (ifc) KO, photoreceptor degeneration was caused by increased DhCer, not reduced levels of Cer (20). Along the same lines, Cer reduction by itself appears to have a positive effect by enhancing myelin repair in acute and chronic demyelination paradigms, as deduced from a model of acid sphingomyelinase deficiency (40). Of note, impairment of the alkaline ceramidase 3 (ACER3), just one step after DEGS1 (Figure 1), causes a recently described form of childhood leukoencephalopathy of similar clinical presentation to the DEGS1-related LD, with an hypomyelinating aspect of the periventricular and deep WM, severe brain atrophy by 5 years of age, and peripheral neuropathy (5). It is intriguing that the plasma profile of the described patient showed mainly accumulation of DhCer, along with various Cer forms and lactosylceramides in lesser extent (5). Further investigations will be necessary to determine the precise molecular mechanisms through which excess of DhCer, may be toxic for myelinating oligodendrocytes or for the biogenesis of the myelin sheath. By the same token, and beyond the plausible direct negative effects of substrate accumulation in this case, we should acknowledge that sphingolipid metabolism constitutes an intricate network coupled in a “metabolic ripple” (16). As such, the loss of a given enzyme function may cause a shift in the substrate specificity of other enzymes in the pathway, leading to increased production of atypical lipid products that may be toxic to the cell (41). This intriguing possibility should be explored for DEGS1, likely by using a systems biology-type of approach, ideally including integration of comprehensive lipidomics and transcriptomics data (42).

A bulk of evidence suggests that fingolimod has potential to become a lead player in
this context. Its success in relapsing-remitting MS relies on its activity as immunosuppressant, acting by sequestering circulating mature lymphocytes to the lymph nodes, and preventing their penetration into the brain and subsequent myelin destruction. Its molecular effects promoting neuron and oligodendrocytes survival are based on the structural similarity of FTY720 to sphingosine, which allows it to work as a bona-fide functional antagonist to S1P receptors (43, 44), and has lately shown to even improve microstructural integrity and myelination in the white matter tracts of human MS patients (45).

In part because of this structural similarity to sphingosine, FTY720 is a pleiotropic drug that also interferes with sphingolipid de novo biosynthesis, mainly by inhibiting ceramide synthase (CerS) (29, 43), the enzyme that converts sphinganine to DhCer, one step prior to DEGS1, and also converts sphingosine to ceramide (Figure 1). There are six CerS orthologs in mammals (46) and nine –due to whole genome duplication- in zebrafish (47). These enzymes transfer a variable length fatty acyl-coenzyme A (CoA) to the amine group of sphinganine or sphingosine. Studies employing genetic manipulations have demonstrated that different CerS isoforms exhibit strong preference for fatty acyl-CoAs with differing carbon chain lengths, although with extensive overlaps. CerS1 exclusively uses 18 carbon (C18) fatty acids, forming C18 (d18:1/18:0) ceramide, whilst CerS2 preferentially forms d18:1/24:0(C24:0) and d18:1/24:1 (C24:1) ceramides. CerS3 synthesizes very long chain ceramides (>C26-Cer), CerS4 forms C18-/C20-/C24-Cer; CerS5 and CerS6 synthesize mostly C14-/C16-/C18-Cer (48, 49). Thus, the broad spectrum of DhCer species accumulated first in the DEGS1 zebrafish model, and then reduced by fingolimod (spanning C13:1 DhCer to C28:0 DhCer, Supplemental Table 2), adds complexity to future studies aiming to identify the drug’s most plausible targets in this model.

Additional experimental evidence supports the protective effect of FTY720 in sphingolipid metabolism-related disorders, such as GLD, which is caused by inactivation of galactosylceramidase (GALC) resulting in the accumulation of the toxic metabolite galactosylsphingosine (psychosine) in the brain. FTY720 treatment attenuated the psychosine-induced demyelination process in mouse organotypic cerebellar slice cultures (50). With this notion in mind, and our proof-of-principle results in a model organism, we posit that FTY720 (or novel, more specific next-generation sphingosine analogs interfering with CerS or other enzymatic steps along the
pathway may provide a promising therapeutic option for white matter disorders linked to *DEGS1* deficiency and perhaps others in sphingolipid metabolism, paving the way for the repurposing of FTY720 for other diseases. Our next step as a DEGS1-consortium is the validation of a robust biomarker in plasma (such as DhCer/Cer ratios) to monitor target engagement upon treatment and to prepare for early clinical intervention aiming to alleviate and modify disease course of this life-threatening condition.
Materials and methods

Patients, Genetic Studies and Ethics Statement

All 19 affected individuals underwent extensive clinical examination by a pediatric neurologist and at least one expert clinical geneticist at their referral hospitals, where broad metabolic and genetic testing was performed. Standardized phenotypic data were collected by review of the clinical histories and follow-up investigations (See Table 1-3). All available clinical and magnetic resonance image (MRI) data were collected and jointly reviewed. Whole-exome sequencing (WES) on an Illumina HiSeq platform were performed according to the following paradigms: (1) trio-based clinical diagnostic WES (individuals 1, 7, 9, 10, 11, 14, 17), (2) trio-based WES or trio-based WES plus affected sibling in a research-based analysis (individuals 3, 4, 15, 18, 19 ), or (3) WES of an affected individual followed by single site testing in parental DNA samples (individuals 6 and 8). Point mutations and indels were confirmed by Sanger sequencing of DNA sample from all available family members, when possible (Supplementary Table 3). The exome sequences have been deposited in public repositories: Patients 4 (phs000711.v5.p1), patients 13 (phs000744.v4.p2), and 18 (phs001272.v1.p1) into dbGaP; patient 1 (P0007232), patient 6 (P0005949), patient 7 (P0007704), patient 8 (P0007705), patient 9 (P0007706), patient 10 (P0007707), and patient 15 (P0007703) into Phenome Central.

Targeted Lipidomics Profiling

Briefly, cells were harvested using trypsin, and cell pellets contained 3-5 million cells. 50 mg muscle biopsy was snap frozen and stored at -80 °C until extraction. The zebrafish samples consisted of a pool of 5 zebrafish larvae (5 dpf) per experimental point (n=4) per condition. Lipidomics experiments were performed at Biocrates Life Science AG, as follows: Fibroblast cells were lysed by freeze-thaw cycles and metabolites were extracted with 60 μl ice-cold methanol. Zebrafish larvae were homogenized using Precellys and metabolites were extracted with 60 μl ice-cold methanol. For measuring metabolite concentrations from muscle tissue, the samples were first weighed and then homogenized using Precellys in methanol. Samples were centrifuged and the supernatant was used for further analysis. Ceramides, dihydroceramides, and 2-hydroxyacyl ceramides were quantitatively analyzed by high-throughput FIA-ESI-MS/MS. The reported lipid annotation represents a sum signal of all isobaric lipids with the same molecular weight (±0.5 Da range) within the same lipid
class. Multiple reaction monitoring (MRM) detection in positive and negative mode was performed using a SCIEX 4000 QTRAP® (SCIEX, Darmstadt, Germany) instrument. Sample preparation of 20 μL sample volume was followed by a MeOH/CHCl3-liquid/liquid-extraction protocol. In addition to five internal standards to compensate for matrix effects, 43 external standards were used for a multi-point calibration. The quantitative data analysis was performed with our in-house software MetIDQ™ enabling isotopic correction. We declare that all pre-analytical and analytical procedures were performed, documented and reviewed according to our ISO 9001:2008 certified in-house quality management rules and guidelines.

**Zebrafish strains**

Zebrafish embryos were obtained by mating of adult fish using standard methods. All fish strains were maintained individually as inbred lines. Wild type zebrafish strain was AB/Tu (RRID: ZIRC_ZL1/RRID: ZIRC_ZL57), and Tg(mbp:egfp) transgenic zebrafish was generated as described (27), in order to visualize myelinating oligodendrocytes in living zebrafish. Embryos were reared at 28.5 °C until processing for analyses at desired stages.

**In situ hybridization and immunolabeling**

Whole-mount in situ hybridization (ISH) was performed with standard protocols, as described previously (51). Embryos were fixed in 4% PFA, cryoprotected in 30% sucrose, and embedded in OCT. Blocks were frozen to improve tissue preservation, and then 10 μm sections were cut on a LeicaCM1510-1 cryostat (Leica). Hybridization was performed at 65°C with digoxigenin-labelled RNA probes. The antisense digoxigenin labelled RNA probe for zebrafish degs1 (ENSDART00000013007.5) was generated by in vitro transcription of an amplicon from exon 1 (primers, forward 5'-ATG GGG AAC CGC GTG GCG CG -3'; reverse, 5' -TCA CTC CTG CTT GAC GTC TC -3'). Following purification, the fragment was cloned into a pBluescript dual promoter vector and was sequenced to confirm identity. The construct was linearized with BamHI, and digoxigenin-labelled antisense mRNA probe was generated by T3 in vitro transcription (DIG-RNA labelling kit, Roche 11-175-025-910). No signal was detected using the sense probe.

For GFP immunolabeling, staged embryos were fixed in 4 % paraformaldehyde (PFA) at room temperature for 20 min, washed in 0.1 % Tween 20/PBS, and incubated
overnight at 4 °C with anti-GFP primary antibody (GFP102; 1:500; Aves Labs) in blocking solution followed by secondary antibodies conjugated with Alexa Fluor 488. Sections were then washed three times in 1X PBS and mounted in Fluoromount (Sigma). Cryostat sections were imaged on a Nikon ECLIPSE 80i fluorescence microscope. ISH and fluorescent images were processed using ImageJ (National Institutes of Health, Bethesda, MD). Confocal images were acquired using a Leica TCS SL laser scanning confocal spectral microscope (Leica Microsystems Heidelberg GmbH, Mannheim, Germany). Calculation of the number of MBP + cells was performed using plugins in ImageJ software. We imaged a fixed area in the spinal cord (dotted box in Figure 5H). MBP + cells (myelinating oligodendrocytes) were counted in the dorsal spinal cord of 4·5 dpf larvae.

**Antisense morpholino injections**

For morpholino knockdowns, embryos were injected with splice-blocking (sb) morpholino oligomers (MOs) obtained from GeneTools LLC (Philomath, OR). MO-degs1, 5´-GCT GAA TAA CTG CTC TCA CCA TTG G-3´ was designed as complementary to the genomic sequence flanking the exon 2-intron 2 boundary. Briefly, 1 nl of 5 ng/nl or 10 ng/nl MO-control and MO-DEGS1 were injected into the yolk of one-cell stage embryos. After injection embryos were incubated at 28·5ºC until the desired stage was reached. Injected embryos and uninjected clutch-mate controls were analyzed from 0 - 5 days post-fertilization (dpf). Every day dead larvae were removed and the fraction of surviving larvae was recorded till 5 dpf. In order to verify the efficiency of the morpholinos, RNA from uninjected, control MO and MO-DEGS1 injected larvae was extracted with Trizol (Thermo Fisher), and reverse transcription was performed with first-strand cDNA synthesis with the QuantiTect Reverse Transcription kit (Qiagen). The targeted region of degs1 was PCR-amplified using primers complementary to sites in flanking exons located in exon 2 (5´- GGC TCT CTG AAC CTG CTG AC -3´) and exon 3 (5´C TT GAC GTC TCC GAC CAG TT-3´), respectively using standard PCR conditions (Ta: 60 °C), and migrated by electrophoresis on a 1 % agarose gel; bands were excised, gel purified using QIAquick gel extraction kit (Qiagen) and resulting clones were Sanger sequenced to confirm aberrant splicing events induced by the MO (Supplementary Figure 4G-I). The standard
MO-control against β-globin was also obtained from GeneTools (5′-CCT CTT ACC TCA GTT ACA ATT TAT A-3′) was used as negative control.

**Larval Locomotor Behavior Assay**

By 5 dpf, zebrafish larvae perform spontaneous swimming and their visual system is fully developed. Uninjected, MO control and MO-DEGS1 120 hpf (hours post fertilization) larvae were transferred to individual wells of 96-well plate with 150 µl fresh fish water and allowed to acclimate for a few hours. The zebrafish larvae behaviour is tracked and analysed by the EthoVision XT software and the DanioVision device from Noldus Information Technologies, Wageningen, The Netherlands. This closed system consists of a camera placed above a chamber with circulating water and a temperature sensor that is set at 28·5 ºC. Individualized larvae in a 96-wells plate are placed in the chamber, which can provide different stimuli (light/dark environment, tapping, sound) controlled by the software. Prior to each experiment, larvae were left for 10 minutes in dark for acclimation, then predetermined series of alternating dark and light environment are presented to the larvae. The natural locomotor behaviour of zebrafish larvae is characterized by high activity in darkness and immobility in light environments. The final 25 min long experimental protocol is divided in 5 min period of darkness, and then two times repeated cycle of 5 min of bright light followed by 5 min of darkness. During the behavioural trial the total distance moved by every larva is measured. We obtained the distance moved and the mobility parameters from EthoVision tracking program analysis, and baseline parameters were subtracted out before. All locomotor assays were performed at 1pm onwards to ensure steady activity of zebrafish (52). After observations, all subjects were euthanized with a lethal concentration of MS-222 Tricaine (ethyl-3-aminobenzoate methane-sulfonate salt; Sigma). Swimming behaviour after drug treatment was performed by adding FTY720 to standard fish water to the final concentration of 3·3, 1·0, 0·3 ng/µl. DMSO was used as vehicle. MO control and MO-DEGS1 embryos (0 hpf) were treated with FTY720 till 120 hpf and behavior assay was performed as described above. All measures were averaged across larvae within each condition (n = 20 larvae/condition) and reported as population means ± SD.

**Statistical analysis**
All experiments were repeated at least 3 times with consistent results. All cell culture data were from biologic triplicates, unless otherwise indicated. Statistical analysis was performed with two-tailed unpaired Student’s t test (*P < 0.05, **P < 0.01, ***P < 0.001), for comparison of 2 groups, and ANOVA followed by Tukey’s post hoc test for multiple comparisons (*P < 0.05, **P < 0.01, ***P < 0.001) after verifying normality. Statistical analyses were performed using the GraphPad Prism 7.0 program.

**Study approval**

Human study:
Human genetic studies conducted in research laboratories were approved by local ethics committees from participating centers (Barcelona, Spain (IDIBELL: PR076/14); Paris, France (INSERM U1163: 2015-03-03/DC 2014-2272; LEUKOFRANCE: CPP AU788; CNIL 1406552; AFSSAPS B90298-60); California, US (University of California, San Diego: IRB 140028), (Peking, China (Peking University First Hospital: [2005]004), Rochester, US (Mayo Clinic: IRB 12-009346), Baltimore, US (Johns Hopkins School of Medicine: NA_00045758); Hamilton, Canada; Ahvaz, Iran (Shahid Chamran University of Ahvaz: EE/97.24.3 17654/scu.ac.ir). Parental (or legal guardian) written informed consent was obtained for all affected children. Written informed consent was provided for the video appearing in supplementary data.

Zebrafish study:
All protocols used have been approved by the Institutional Animal Care and Use Ethic Committee (PRBB–IACUEC) and implemented according to national and European regulations. All experiments were carried out in accordance with the principles of the 3Rs.
Authors’ contributions
DP, NL, SF, JJ, MR, CCo, DR, JT and CP performed and/or interpreted or supervised aspects of the different experiments. SAA, MEY, CC, MJW, DV, GL, KSP, IDe, HY, JW, MB, LB, MT, KNJ, DM, MSZ, MCP, BCL, EWK, FPV, EW, NLMS, JSC, RM, HG, NM, GS, LC, DRo, JGG, AF, OBT undertook clinical and genealogical studies and provided clinical data and biological specimens from patients. ID and AS undertook variant calling and bioinformatic analyses on whole exome sequencing data. DP and AP analyzed and interpreted data and wrote the initial draft of the manuscript. OBT supervised the clinical and MRI data in coordination with AP. AP provided overall study direction, funding, coordination, supervision, and revised the manuscript. All authors critically reviewed the report and approved the final version.

Supplementary Data
Supplementary Data include material and methods, 4 Figures, 3 tables and 1 video.

Acknowledgements
We thank CERCA Program/ Generalitat de Catalunya for institutional support. We also thank Juanjo Martínez and Cristina Guilera for excellent technical assistance and Asociación Española contra las Leucodistrofias (ALE-ELA España). We are indebted to the NIH NeuroBioBank for supplying the case material used for the human studies. The authors thank the affected individuals and their families for participation in this study. This study was supported by the ISCIII [FIS PI14/00581] (Co-funded by European Regional Development Fund. ERDF, a way to build Europe), ‘La Marató de TV3’ Foundation 345/C/2014 (to A.P., CC and C.P.), the Hesperia Foundation and CIBER on Rare Diseases (CIBERER) [ACCI14-759] and the Secretariat for Universities and Research of the Ministry of Business and Knowledge of the Government of Catalonia [2017SGR1206] to A.P.; Spanish Ministry of Economy and Competitiveness (MINECO-FEDER): BFU2015-67400-P to C.P., the Spanish Institute for Health Carlos III [Miguel Servet program CPII16/00016] to S.F. and the Center for Biomedical Research on Rare Diseases (CIBERER) to N.L. and M.R., and a predoctoral fellowship awarded from the Government of Catalonia through L’Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR; FI-DGR 2014) to D. P. X.J. acknowledges a Sara Borrell postdoctoral fellowship from Instituto de Salud Carlos III. Grants to L.C.: National Research Agency (ANR-10-IAHU-01) and Fondation pour la Recherche
Médicale (DEQ20160334938). The authors thank the members of LEUKOFRANCE, particularly the Biobank in Clermont Ferrand (Eleonore Pierre and Philippe Vago) and Kremlin Bicetre (Elise Lebigot and Abdelhamid Slama) University Hospitals. Grants to OBT: European Union FP7 RD-Connect project, ELA Foundation (2009-007I4AV2) and “Les amis de Ianis” association (Ploudaniel, France). ID was supported by an ELA grant and is currently supported by the RD-connect project. M.J.W.: The views expressed herein are my own and do not necessarily reflect the official policy or position of the Department of the Navy, Department of Defense, or the U.S. Government. J.G.G.: NIH grants P01HD070494, 1R01NS098004, R01NS048453, R01NS052455, and UL1TR001866 from the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH) Clinical and Translational Science Award (CTSA) program, the Simons Foundation Autism Research Initiative (275275), Howard Hughes Medical Institute, Qatar National Research Foundation NPRP 6-1463-3-351. We thank Yale University Center for Mendelian Genomics (Mark Gerstein, Murat Gunel, Richard P. Lifton, Shrikant M. Mane, 5UM1HG006504) and the Broad Institute (Daniel G. MacArthur and Heidi L Rehm, 5UM1HG008900) for sequencing support. NS: National Institutes of Health grant 1U54 HG006542. The Baylor-Hopkins Center for Mendelian Genomics and GeneMatcher are supported by a grant from the National Human Genome Research Institute, 1U54HG006493. AF: Grants from the Kennedy Krieger Institute Intellectual and Developmental Disabilities Research Center grant (funded through NICHD U54 HD079123). MB: National Institutes of Health grants NS056780 (MB) and the National Ataxia Foundation. MCP: Grants from the National Institutes of Health (NS 65768-01), the Peggy Furth Fund, the National MS Society. EWK: Mayo Clinic Center for Individualized Medicine (CIM), the Investigative and Functional Genomics Program and the William O. Lund, Jr. and Natalie C. Lund Charitable Foundation. MAT: Genetic testing was performed under the Care4Rare Canada Consortium funded by Genome Canada, the Canadian Institutes of Health Research, the Ontario Genomics Institute, Ontario Research Fund, Genome Quebec and Children's Hospital of Eastern Ontario Foundation. We wish to acknowledge the contribution of the high throughput sequencing platform of the McGill University and Génome Québec Innovation Centre, Montréal, Canada. We are grateful to Dr. Cheol-Hee Kim for providing the Tol2
transposon vector, Bellvitge Biobank for providing control human muscle tissues. AP and EWK are members of the Undiagnosed Diseases Program International (UDNI).

Conflict of Interest
The authors declare that this article was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

URLs
1000 Genomes, http://phase3browser.1000genomes.org/index.html
CADD, http://cadd.gs.washington.edu/
Clustalw, http://www.clustal.org/
Database of Genomic Variants, http://dgv.tcag.ca/dgv/app/home/
DECIPHER, https://decipher.sanger.ac.uk/
Ensembl Genome Browser, https://www.ensembl.org/index.html
EVS, http://evs.gs.washington.edu/EVS/
Fiji, https://fiji.sc/
GATK, https://software.broadinstitute.org/gatk/
Genematcher, https://genematcher.org/
GME Variome (http://igm.ucsd.edu/gme/)
Gnomad browser, http://gnomad.broadinstitute.org/
Graphpad, https://www.graphpad.com/
HGVS, http://varnomen.hgvs.org
Human Genotype-Tissue Expression portal https://www.gtexportal.org
Iranome (http://www.iranome.ir/) GME Variome (http://igm.ucsd.edu/gme/)
Mouse brain atlas http://mouse.brain-map.org/
Polyphen-2, http://genetics.bwh.harvard.edu/pph2/
SIFT, http://sift.bii.a-star.edu.sg/
The Human Protein Atlas, http://www.proteinatlas.org/
UCSC Genome Browser, http://genome.ucsc.edu
Uniprot, http://www.uniprot.org/
Zfin, https://zfin.org
References


Figure legends

Figure. 1. Scheme depicting enzyme defects associated with neurological disorders in the sphingolipid metabolism pathway, and Fingolimod (FTY720) action. Serine palmitoyltransferase (SPT) catalyzes the initial reaction of the de novo sphingolipid pathway. Dihydrosphingosine is produced after an intermediate step regulated by 3-keto-dihydrosphingosine reductase (KDS), which is then followed by acylation by ceramide synthase (CerS) to produce dihydroceramide. The final reaction is the addition of a double bond by dihydroceramide desaturase DEGS1 to form ceramide. Ceramide is metabolized by ceramidase (CDse) to generate sphingosine, which in turn produces sphingosine 1-phosphate through phosphorylation by sphingosine kinase-1 and sphingosine kinase-2 (SphK1/2). Sphingosine 1-phosphate can be catabolized into hexadecenal and ethanolamine phosphate by sphingosine 1-phosphate lyase (S1PL).
Ceramide can be generated by the breakdown of sphingomyelin (SM) by acid (ASM) or neutral sphingomyelinases (NSM). Fingolimod (FTY720) has inhibitory effects on CerS. Enzyme (in bold) defects are indicated by solid bars across the blue arrows. The names of diseases are given (red box). SPT, serine palmitoyltransferase; KDS, 3-keto-dihydrosphingosine reductase; CerS, ceramide synthase; DEGS1, dihydroceramide desaturase; HSN1, hereditary sensory neuropathy type I; MLD, metachromatic leukodystrophy; PD, Parkinson disease; GalCer, galactosylceramide; Sap, saposin.

Figure 2. Schematic representation of human DEGS1 (NP_003667.1) and its functional domains with variants identified in patients. (A) DEGS1 has 323 amino acids. Numbers under the protein line indicate the boundaries of each domain. The lipid
DES domain (red) of DEGS1 comprises amino acids 6-42. The histidine domain
(orange) of DEGS1 comprises amino acids 89-93, 128-132, and 259-263. The
transmembrane domain (green) of DEGS1 comprises amino acids 43-62, 68-92, 104-
122, 150-172, 184-202, and 210-231. The fatty acid desaturase (FAD) domain covers
amino acids 64-293. Multiple protein sequence alignment of DEGS1 orthologs show
conservation of missense mutations detected in cases (bottom). (B) Schematic of the
human DEGS1 locus which consists of three exons. The alignment was performed from
different species is shown (bottom). The lipid DES, transmembrane and histidine
domain are indicated by red, green and orange shading respectively. The alignment was
performed with ClustalW using the following RefSeq numbers: NP_003667.1, Homo
sapiens; NP_031879.1, Mus musculus; NP_445775.2, Rattus norvegicus;
NP_001007485.1, Xenopus tropicalis; NP_997865.1, Danio rerio; NP_476594.1,
Drosophila melanogaster; NP_493549.1, Caenorhabditis elegans.
Figure 3. Brain MRIs according to clinical severity and follow up.
(A) MRIs of patients with distinct clinical severity at the age of 6 years. Patient 7 (Top row) shows the mildest presentation with walking acquisition and spastic paraplegia. In FLAIR sequences, mild hyperintensities of the periventricular white matter (WM), with normal CC and internal capsule. In T1 sagittal, normal cerebellum and CC. Patient 9 (low row) was able to hold the head but develop dystonia and spasticity with failure to thrive (−4SD). Despite this severe clinical presentation, the FLAIR sequences show an abnormal hypersignal of the white matter only in the periventricular and deep regions that are atrophic. The CC and the cerebellar vermis are atrophic.

(B) Sequential MRIs of patient 16. At 6 months all the WM structures including the cerebellum, the brainstem and the CC appear unmyelinated. The CC is thin on the T1 sagittal section. A progression in the myelination has occurred at 2.5 y of age but the posterior part of the internal capsules is not myelinated, with periventricular hypersignals and an isosignal of the deep and subcortical WM and atrophic thalami. At 4 years of age the internal capsules, the deep and subcortical WM show normal myelinated signal whereas the thalami appeared in hypersignal and atrophic, as well as the cerebellar vermis.
Figure 4. Dihydroceramides and ceramides imbalance in human patient fibroblasts (P4, P7, P9) and muscle (P3). (A) Ceramides (Cer), dihydroceramides (DhCer), and the ratios DhCer/Cer in human controls (n=9) and patient fibroblasts (n=3) and (B) in human controls (n=5) and patient muscle (n=1). Data are represented as percentage of total ceramides and dihydroceramides. (C) Intracellular ROS was quantified using the H2DCFDA probe in patient fibroblasts (patients 4, 7 and 9) and
controls (n=5) at a basal level† (D) Exogenous DhCer (C18:0) treatment (20 µM, 6h) was applied to control and patient’s fibroblasts. Antimycin was used as positive control for ROS generation++. The fibroblasts results are from three independent experiments and they have been performed in triplicate. Data are shown as the means ± SD * p<0·05; ** p<0·01; *** p<0·001 after one-way ANOVA+ or two-way ANOVA++ test followed by Tukey’s post hoc test.

Figure 5. Impact of Degs1 knockdown in Danio rerio larvae

(A) Ceramides (Cer), dihydroceramides (DhCer), and the ratios DhCer/Cer in zebrafish MO-control and MO-DEGS1, n=4/condition (5 larvae per tube/condition), at 5 dpf+. Data are represented as percentage of total ceramides and dihydroceramides. (B) Representative images of the normal (blue), mild (purple), and severe (orange) phenotypes observed in the control and MO-DEGS1 injected groups. Scale bar: 10 μm.
(C) Quantification at 5 dpf of the percentage of normal, mild, and severe phenotype groups obtained. Values are the percentage ± SD of the three independent experiments with n = 50 animals per group per experiments. (D) Examples of digital tracks of 10 single larvae of each condition shown in red. (E) Scatter plot displaying the total movement distance by different larvae (uninjected larvae (n=20): 1564.4 mm ± 321.6, MO-control (n=30): 1146.6 mm ± 255.2, MO-DEGS1 (n=33): 28.3 mm ± 24.5)**. (F-H) Dorsal views of larvae injected with control and MO-DEGS1, and (F’-H’) inserts of boxed areas at 4.5 dpf. Scale bar: 100 μm. White arrows indicate MBP⁺ cells (myelinating oligodendrocytes). (I) Illustration of the tg(mbp:EGFP) larvae. (J) Scatter plot displaying the number of MBP⁺ in the dorsal spinal cord of 4.5 dpf larvae (MO-control: n=30, MO-DEGS1: n=28, MO-DEGS1+1 ng/µl FTY720: n=19)**. Data are shown as the means ± SD; * p<0.05; ** p<0.01; *** p<0.001 after two-tailed unpaired Student’s t test* or one-way ANOVA** test followed by Tukey’s post hoc test.

Figure 6. FTY720 ameliorates locomotor, biochemical and cellular phenotype in MO-DEGS1 larvae and lowers ROS levels in patient’s fibroblasts. (A) MO-DEGS1 larvae were treated for 120 h with fingolimod (FTY720) at 0.3, 1.0 and 3.3 ng/µl. Digital tracks of larvae are shown in red. (B) Scatter plot (n=20 by condition) showing total movement distance (mm) upon FTY720 treatment**. Total movement distance
(mm) traveled by MO control (veh. 1268·2 mm ± 402·9); (FTY720, 1230 mm ± 365·2); compared to MO-DEGS1 (veh. 44·6 mm ± 39·2) and the different treatment doses (FTY720 3.3 ng/µl, 542·3 mm ± 238·8; FTY720 1ng/µl, 615·3 mm ± 330·8; FTY720 0.3ng/µl, 670·3 mm ± 476·6). (C) Ceramides (Cer), dihydroceramides (DhCer), and the ratios DhCer/Cer in zebrafish MO-control and MO-DEGS1 treated with 1 ng/µl of FTY720 (n=4 (5 larvae per tube/condition) larvae/condition at 5 dpf ++). Data are represented as percentage of total ceramides and dihydroceramides. The results are from three independent experiments. (D) Intracellular ROS is partially normalized by FTY720 in patient fibroblasts++ (n=3) compared to controls (n=3). Data are shown as the means ± SD; * p<0·05; ** p<0·01; *** p<0·001 after one-way+ or two-way+++ ANOVA test followed by Tukey’s post hoc test.
<table>
<thead>
<tr>
<th>Family</th>
<th>Family 1</th>
<th>Patient number</th>
<th>Patient 1</th>
<th>Patient 2</th>
<th>Patient 3</th>
<th>Patient 4</th>
<th>Patient 5</th>
<th>Patient 6</th>
<th>Patient 7</th>
<th>Patient 8</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mutations</td>
<td>c.395A&gt;G: p.(His132Arg)</td>
<td>c.395A&gt;G: p.(His132Arg)</td>
<td>2 affected siblings</td>
<td>5 unaffected siblings</td>
<td>2 affected siblings</td>
<td>3 unaffected siblings</td>
<td>2 affected siblings</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ethnicity</td>
<td>Pakistani</td>
<td>European</td>
<td>Caucasian</td>
<td>European Caucasian</td>
<td>Moroccan</td>
<td>Moroccan</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Consanguinity</td>
<td>yes</td>
<td>no</td>
<td>no</td>
<td>yes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Family members</td>
<td>2 affected siblings</td>
<td>5 unaffected siblings</td>
<td>2 affected siblings</td>
<td>3 unaffected siblings</td>
<td>2 affected siblings</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient number</td>
<td>Patient 1</td>
<td>Patient 2</td>
<td>Patient 3</td>
<td>Patient 4</td>
<td>Patient 5</td>
<td>Patient 6</td>
<td>Patient 7</td>
<td>Patient 8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sex</td>
<td>M</td>
<td>M</td>
<td>F</td>
<td>F</td>
<td>M</td>
<td>F</td>
<td>M</td>
<td>M</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Death (age)</td>
<td>no</td>
<td>yes (7y)</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>yes (4 y)</td>
<td>no</td>
<td>no</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age at last exam</td>
<td>6 y</td>
<td>7 y</td>
<td>9 y</td>
<td>9 y</td>
<td>6 y</td>
<td>4 y</td>
<td>13 y</td>
<td>9 y</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age of onset (months)</td>
<td>2</td>
<td>0.5</td>
<td>12</td>
<td>6</td>
<td>6</td>
<td>1</td>
<td>24</td>
<td>24</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Term</td>
<td>34 WG</td>
<td>35 WG</td>
<td>38 WG</td>
<td>38 WG</td>
<td>39 WG</td>
<td>38 WG</td>
<td>39 WG</td>
<td>38 WG</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Birth WT; HT; OFC</td>
<td>2710g; 47cm; 37cm</td>
<td>2400 g; 46 cm; 35 cm</td>
<td>4025 g; na; na</td>
<td>3883 g; 55.9 cm; na</td>
<td>4054 g; na; na</td>
<td>3200 g; 48.3 cm; na</td>
<td>3.115g; 50 cm; 35 cm</td>
<td>3.600 g; 49 cm; 35 cm</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Motor acquisitions (age)</td>
<td>none</td>
<td>none</td>
<td>sit unassisted (6m)</td>
<td>hold head; sit with support</td>
<td>hold head; sit with support</td>
<td>none</td>
<td>walking without support short distance (2 y)</td>
<td>walking with support (2 y)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Motor developmental score (MDS)</td>
<td>0</td>
<td>0</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>4</td>
<td>3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Language acquisitions(age)</td>
<td>none</td>
<td>none</td>
<td>simple sentences</td>
<td>few words (1y)</td>
<td>none</td>
<td>2 words associated sentences (5y)</td>
<td>simple reading sentences</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Regression (age)</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>1 y</td>
<td>no</td>
<td>no</td>
<td>10 y</td>
<td>no</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neurological signs</td>
<td>ax/limb dys; sp</td>
<td>ax/limb dys; sp</td>
<td>limb dys; sp; dysarthria</td>
<td>limb dys; sp</td>
<td>limb dys; sp</td>
<td>ax dys</td>
<td>sp; dysmetria</td>
<td>sp; dysmetria; dysarthria</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eyes abnormalities</td>
<td>slow pendular ocular movements; optic atrophy</td>
<td>slow pendular ocular movements</td>
<td>anisocoria</td>
<td>Nystagmus and abnormal saccades. Mild optic atrophy</td>
<td>none</td>
<td>nystagmus (1m) then no fixation</td>
<td>none</td>
<td>none</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acquired microcephalia (SD)</td>
<td>no (-2)</td>
<td>yes (-3)</td>
<td>no (0)</td>
<td>no (0)</td>
<td>no (0)</td>
<td>no (0)</td>
<td>no (0)</td>
<td>no (0)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Failure to thrive (SD Weight; SD Height)</td>
<td>yes (-4 W; -4 H)</td>
<td>yes (-4 W; -4 H)</td>
<td>yes (-2 W; -4H)</td>
<td>yes (-4 W; -4 H)</td>
<td>yes (-4 W; -4 H)</td>
<td>na</td>
<td>no (+1 W; +1 H)</td>
<td>no (-1 W; -1 H)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gastrostomia</td>
<td>yes (2 y; no gain)</td>
<td>yes (4 y; no gain)</td>
<td>Formula fed</td>
<td>yes (2y gain)</td>
<td>yes (4 y few gain)</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Seizures (onset age)</td>
<td>none</td>
<td>none</td>
<td>Partial complex and clonic</td>
<td>clonic tonic severe (22m) status epilepticus. Stop Ketogenic diet (5y)</td>
<td>clonic tonic (2y). Stop ketogenic diet (2y)</td>
<td>myoclonic</td>
<td>none</td>
<td>partial complexes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other signs</td>
<td>none</td>
<td>Died suddenly of unrecognized cause</td>
<td>Hip dysplasia</td>
<td>Premature pubarche</td>
<td>Kyphosis and scoliosis</td>
<td>Kyphosis and scoliosis</td>
<td>none</td>
<td>none</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abnormal nerve conduction velocities (&lt;35m/s)</td>
<td>yes (3y)</td>
<td>yes (6y)</td>
<td>no (8y)</td>
<td>na</td>
<td>na</td>
<td>na</td>
<td>no (8 y)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Long latencies of central conduction velocities (&gt;21DS)</td>
<td>na</td>
<td>na</td>
<td>na</td>
<td>na</td>
<td>na</td>
<td>na</td>
<td>na</td>
<td>BAEP; SEP</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 1. Clinical description of family 1 to 5 (BAEP: Brain stem auditory potentials; VEP: visual evoked potentials; SEP: Somatosensory evoked potentials; W: weight; H: height; OFC: occipitofrontal circumference; dys: dystonia; sp: spasticity; y: year; m month; nl: normal; na: not available; motor development score (0: no acquisition; 1 hold the head; 2 sit position without support; 3 walk with support; 4 walk unaided)).
<table>
<thead>
<tr>
<th>Family</th>
<th>Family 6</th>
<th>Family 7</th>
<th>Family 8</th>
<th>Family 9</th>
<th>Family 10</th>
<th>Family 11</th>
<th>Family 12</th>
<th>Family 13</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ethnicity</td>
<td>Algerian</td>
<td>Algerian</td>
<td>Egyptian</td>
<td>Indian</td>
<td>European</td>
<td>Caucasian</td>
<td>Chinese</td>
<td>Egyptian</td>
</tr>
<tr>
<td>Consanguinity</td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
<td>no</td>
<td>no</td>
<td>yes</td>
<td>yes</td>
</tr>
<tr>
<td>Family members</td>
<td>1 unaffected sibling</td>
<td>2 affected siblings died &lt;14 y, 2 healthy siblings</td>
<td>3 affected siblings</td>
<td>1 unaffected sibling</td>
<td>2 affected siblings</td>
<td>1 unaffected sibling</td>
<td>no sibling</td>
<td>no sibling</td>
</tr>
<tr>
<td>Sex</td>
<td>F</td>
<td>M</td>
<td>F</td>
<td>M</td>
<td>M</td>
<td>M</td>
<td>M</td>
<td>F</td>
</tr>
<tr>
<td>Death (age)</td>
<td>no</td>
<td>no</td>
<td>yes (5 y)</td>
<td>yes (2.5 y)</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>no</td>
</tr>
<tr>
<td>Age at last exam</td>
<td>9 y</td>
<td>20 y</td>
<td>3 y</td>
<td>2.5 y</td>
<td>4 y</td>
<td>18 y</td>
<td>1 y</td>
<td>4 y</td>
</tr>
<tr>
<td>Age of onset (months)</td>
<td>1</td>
<td>1</td>
<td>4</td>
<td>1</td>
<td>4</td>
<td>4</td>
<td>4</td>
<td>5</td>
</tr>
<tr>
<td>Term</td>
<td>37WG</td>
<td>40 WG</td>
<td>39 WG</td>
<td>38 WG</td>
<td>38 WG</td>
<td>39 WG</td>
<td>39 WG</td>
<td>40 WG</td>
</tr>
<tr>
<td>Birth WT; HT; OFC</td>
<td>3280 g; 49 cm; 34 cm</td>
<td>3700g; 50cm; 36 cm</td>
<td>3500g; 48cm; 34 cm</td>
<td>3650g; 50cm; 35.5 cm</td>
<td>3100g; 51cm; 35cm</td>
<td>3300 g; 55 cm. na</td>
<td>3401g; na; na</td>
<td>3515g; na; na</td>
</tr>
<tr>
<td>Motor acquisitions (age)</td>
<td>hold head; sit with support</td>
<td>hold head; sit with support</td>
<td>none</td>
<td>none</td>
<td>none</td>
<td>sit unassisted (5 m)</td>
<td>hold head; sit with support</td>
<td>hold head; sit with support</td>
</tr>
<tr>
<td>MDS</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>2</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>language acquisitions(age)</td>
<td>none</td>
<td>none</td>
<td>none</td>
<td>none</td>
<td>none</td>
<td>single words (2y)</td>
<td>none</td>
<td>none</td>
</tr>
<tr>
<td>Regression (age)</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>6m</td>
<td>no</td>
<td>no</td>
</tr>
<tr>
<td>Neurological signs</td>
<td>limb dys; sp</td>
<td>ax/limb dys; sp</td>
<td>limb dys; sp</td>
<td>limb dys; sp</td>
<td>limb dys; sp</td>
<td>choreoathetosis; sp</td>
<td>sp</td>
<td>sp</td>
</tr>
<tr>
<td>Eyes abnormalities</td>
<td>nystagmus (1m), 1 episode of tonic-oppauge like (8y), ERG nl</td>
<td>nystagmus (1m)</td>
<td>ERG nl</td>
<td>nystagmus (1m)</td>
<td>ERG nl</td>
<td>nystagmus(1m)</td>
<td>ERG nl</td>
<td>nystagmus (4m)</td>
</tr>
<tr>
<td>Acquired microcephalia (SD)</td>
<td>no (-2)</td>
<td>no (-2)</td>
<td>no (-2)</td>
<td>no (-2)</td>
<td>no (+1)</td>
<td>na</td>
<td>no (+1)</td>
<td>no (+1)</td>
</tr>
<tr>
<td>Failure to thrive (SD Weight; SD Height)</td>
<td>yes (-3.5 w; -4 H)</td>
<td>yes (-5 W; -5 H)</td>
<td>yes (-4 W; -4 H)</td>
<td>yes (-4W; -4H)</td>
<td>no (-2 W; -2H)</td>
<td>yes (-6 W; -6 H)</td>
<td>no (-1W; 0 H)</td>
<td>no (-2 W; -1 H)</td>
</tr>
<tr>
<td>Gastrostomia</td>
<td>no</td>
<td>yes (18y)</td>
<td>Feeding difficulties</td>
<td>Feeding difficulties</td>
<td>Feeding difficulties</td>
<td>yes (1 y)</td>
<td>yes (1 y)</td>
<td>yes (2.5 y)</td>
</tr>
<tr>
<td>Seizures (onset age)</td>
<td>clonic tonic (8m) with status epilepticus</td>
<td>myoclonic (2 y)</td>
<td>partial and myoclonic (3y)</td>
<td>tonic, atonic (8 m)</td>
<td>tonic clonic (5y)</td>
<td>tonic clonic</td>
<td>none</td>
<td>tonic clonic</td>
</tr>
<tr>
<td>Other signs</td>
<td>gingival hypertrophy, scoliosis &amp; hip dislocation &gt; 4.5 years of age.</td>
<td>gingival hypertrophy. Severe scoliosis and joint contractions</td>
<td>Hemorrhagic infarction at the age of 3, coma for 10 days, severe deterioration</td>
<td>Died suddenly of unrecognized cause</td>
<td>joints contractures</td>
<td>Skin hypopigmentation.</td>
<td>none</td>
<td>Skin hypopigmentation.</td>
</tr>
<tr>
<td>Abnormal nerve conduction velocities</td>
<td>no (1 y); yes (2y)</td>
<td>yes (3y)</td>
<td>no (4y)</td>
<td>na</td>
<td>na</td>
<td>no (1y)</td>
<td>no (4y)</td>
<td>yes (6y)</td>
</tr>
<tr>
<td>Long latencies of central conduction</td>
<td>VEP, BAEP</td>
<td>VEP, BAEP</td>
<td>VEP</td>
<td>VEP</td>
<td>VEP</td>
<td>VEP</td>
<td>VEP</td>
<td>BAEP</td>
</tr>
</tbody>
</table>
Table 2. Clinical description of family 6 to 13 (BAEP: Brain stem auditory potentials; VEP: visual evoked potentials; SEP: Somatosensory evoked potentials; W: weight; H: height; OFC: occipitofrontal circumference; dys: dystonia; sp: spasticity; y: year; m month; nl: normal; na: not available; motor development score (0: no acquisition; 1 hold the head; 2 sit position without support; 3 walk with support; 4 walk unaided)).
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>MRI (age of acquisition)</td>
<td>5m</td>
<td>6y</td>
<td>8 y</td>
<td>2y; 4 y</td>
<td>2 y</td>
<td>1 y</td>
<td>6 y</td>
<td>8 y</td>
<td>8m; 2,5 y; 6 y</td>
<td>2 y; 12 y</td>
<td>2 y; 3 y</td>
<td>1 y</td>
<td>10 m</td>
<td>17 y</td>
<td>11 m</td>
<td>6m; 2,5 y; 4y</td>
<td>8m; 16m</td>
<td>6 y</td>
<td>10y</td>
</tr>
<tr>
<td>hypomyelination according to age on the last MRI</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>cerebellum</td>
<td>+</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>+</td>
<td>no</td>
<td>+</td>
<td>no</td>
<td>+</td>
<td>+</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>na</td>
<td>No</td>
</tr>
<tr>
<td>brainstem</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>+</td>
<td>no</td>
<td>+</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>na</td>
<td>No</td>
</tr>
<tr>
<td>cc</td>
<td>+</td>
<td>+</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>+</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>+/-</td>
<td>no</td>
<td>+</td>
<td>na</td>
<td>+/-</td>
</tr>
<tr>
<td>internal capsules</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>+</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>+</td>
<td>no</td>
<td>no</td>
<td>+</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>+</td>
<td>no</td>
<td>na</td>
</tr>
<tr>
<td>periventricular WM</td>
<td>no</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>na</td>
<td>+</td>
<td>na</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>deep WM</td>
<td>no</td>
<td>+</td>
<td>no</td>
<td>+</td>
<td>+/-</td>
<td>+</td>
<td>no</td>
<td>no</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>no</td>
<td>+</td>
<td>+</td>
<td>na</td>
<td>+</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>subcortical WM</td>
<td>no</td>
<td>+/-</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>+/-</td>
<td>na</td>
<td>no</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>myelin progression</td>
<td>na</td>
<td>na</td>
<td>na</td>
<td>yes</td>
<td>na</td>
<td>na</td>
<td>na</td>
<td>na</td>
<td>na</td>
<td>na</td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
<td>na</td>
<td>na</td>
<td>na</td>
<td>na</td>
<td>na</td>
<td>na</td>
</tr>
<tr>
<td>Basal ganglia abnormalities</td>
<td>hyper T2 thalami</td>
<td>hypo T2 pallidi; atrophy hyper T2 thalami</td>
<td>no</td>
<td>atrophy hyper T2 thalami</td>
<td>atrophy hyper T2 thalami</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>atrophy hyper T2 thalami</td>
<td>atrophy hyper T2 thalami</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>atrophy hyper T2 thalami</td>
<td>hyper T2 dentate nucleus, hyper T2 thalami</td>
<td>mild atrophy hyper Flair thalami</td>
<td>atrophy hyper T2 thalami</td>
<td>na</td>
<td>hypo T2 pallidi; atrophy hyper T2 thalami</td>
</tr>
<tr>
<td>other</td>
<td>hypo T1 in the occipital deep WM/subcortical junction</td>
<td>none</td>
<td>none</td>
<td>none</td>
<td>none</td>
<td>none</td>
<td>none</td>
<td>none</td>
<td>none</td>
<td>none</td>
<td>none</td>
<td>none</td>
<td>none</td>
<td>none</td>
<td>none</td>
<td>na</td>
<td>na</td>
<td>no</td>
<td></td>
</tr>
<tr>
<td>calcifications (CT scan)</td>
<td>no</td>
<td>yes (periventricular)</td>
<td>na</td>
<td>na</td>
<td>na</td>
<td>na</td>
<td>na</td>
<td>na</td>
<td>na</td>
<td>na</td>
<td>no</td>
<td>no</td>
<td>yes (cerebellum)</td>
<td>yes (cerebellum)</td>
<td>yes (cerebellum)</td>
<td>na</td>
<td>no</td>
<td>no</td>
<td>na</td>
</tr>
<tr>
<td>atrophy</td>
<td>cerebellum</td>
<td>no</td>
<td>++</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>+</td>
<td>++</td>
<td>+</td>
<td>+</td>
<td>no</td>
<td>+</td>
<td>no</td>
<td>+</td>
<td>na</td>
<td>++</td>
</tr>
<tr>
<td>ventricule dilatation</td>
<td>+</td>
<td>+</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>+</td>
<td>+</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>+</td>
<td>no</td>
<td>+</td>
<td>no</td>
<td>+</td>
<td>na</td>
</tr>
<tr>
<td>cortical</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>+ (frontal and sylvian fissures)</td>
<td>+</td>
<td>(sylvian fissures)</td>
<td>+ (sylvian fissures)</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>na</td>
<td>++ (frontal and sylvian fissures)</td>
</tr>
<tr>
<td>CC</td>
<td>no</td>
<td>++</td>
<td>no</td>
<td>+ (splenium)</td>
<td>+ (splenium)</td>
<td>+</td>
<td>no</td>
<td>no</td>
<td>+</td>
<td>++</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>(splenium)</td>
<td>na</td>
<td>++</td>
<td></td>
</tr>
<tr>
<td>MRS</td>
<td>NAA</td>
<td>na</td>
<td>na</td>
<td>na</td>
<td>na</td>
<td>na</td>
<td>na</td>
<td>na</td>
<td>na</td>
<td>na</td>
<td>na</td>
<td>na</td>
<td>na</td>
<td>na</td>
<td>na</td>
<td>na</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NAA</td>
<td>nl</td>
<td>low</td>
<td>nl</td>
<td>low</td>
<td>low</td>
<td>low</td>
<td>low</td>
<td>low</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Choline</td>
<td>high</td>
<td>high</td>
<td>high</td>
<td>high</td>
<td>high</td>
<td>high</td>
<td>high</td>
<td>high</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>lactates</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+/-</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Table 3. MRI description (WM: white matter; + present; WR: Virchow Robin; y: year; m month; nl: normal; na: not available).